VYCRINSA

Class [005]
Pharmaceutical preparations for human use for the treatment of Huntington's Disease, chorea associated with Huntington's Disease, schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephalopathy with continuous spike-and-wave during sleep, SCN8A-related epilepsy with encephalopathy, focal onset seizures, Parkinson's Disease, adjunctive treatment of Parkinson's Disease, Major Depressive Disorder, anhedonia in Major Depressive Disorder, inadequate response to treatment in Major Depressive Disorder, dyskinetic cerebral palsy, and neuroimmunological and neuroendocrinological diseases, disorders, and conditions, tardive dyskinesia, dystonia, tics, Tourette syndrome; pharmaceutical preparations for the diagnosis, prevention and treatment of psychiatric disorders, neurological disorders, hormonal disorders, genetic disorders and endocrine disorders, namely, congenital adrenal hyperplasia and adrenal insufficiency; pharmaceutical preparations for human use for diagnosis, prevention and treatment of diseases and disorders by gene therapy; pharmaceuticals for human use for the treatment of rare and orphan diseases, disorders and conditions namely, rare pediatric epilepsies, SCN8A developmental and epileptic encephalopathy, and congenital adrenal hyperplasia; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia.